real peptides FAQ

Administer VIP during the antigen presentation phase or within the first 7–10 days of disease induction. Not after peak inflammation. In EAE models, VIP given at disease onset reduces severity scores by 40–60%, but administration after peak paralysis (day 14–16) produces minimal effect because tissue damage and axonal loss are irreversible. The mechanism is preventive modulation of T-cell differentiation, not reversal of established pathology. If your protocol requires therapeutic intervention after symptom onset, consider pairing VIP with remyelination-promoting agents or neuroprotective compounds targeting distinct pathways.

Do not reconstitute or use the peptide. Document the condition immediately with photographs showing the package interior, gel pack state, and any temperature indicators if included. Contact Real Peptides within 24 hours to initiate a replacement shipment. Peptides exposed to prolonged ambient temperature (>25°C for >4 hours) undergo partial denaturation that mass spectrometry cannot detect. The amino acid sequence remains intact but tertiary structure is compromised, reducing binding affinity unpredictably. Attempting to use a heat-exposed peptide introduces uncontrolled variability into your experimental protocol; replacement is the only scientifically sound option.

Freeze the reconstituted solution in small aliquots at −20°C or −80°C to extend stability beyond the 30-day refrigerated window. Divide the total volume into single-use aliquots immediately after reconstitution. Freeze-thaw cycles degrade peptide integrity, so each aliquot should contain exactly the amount needed for one dosing event. Use cryovials with airtight seals to prevent moisture contamination during frozen storage. A 2014 stability study in the Journal of Pharmaceutical Sciences found that follistatin retained >90% biological activity after six months at −80°C when stored in single-use aliquots, but lost 40–60% activity after three freeze-thaw cycles. Never refreeze a thawed aliquot.

Use a validated cold chain container that maintains 2–8°C for the entire transport duration. Insulated lunch boxes with ice packs are insufficient. Temperature loggers show these setups frequently exceed 12°C during transport, which accelerates peptide degradation. Purpose-built medication coolers or laboratory cold chain shipping containers with phase-change refrigerant maintain stable temperature for 24–48 hours. At Real Peptides, we've guided research teams through transport protocols for sensitive compounds like Thymalin and Cerebrolysin. Temperature stability during transport is as critical as storage stability.

The 2026 trials used 10mg intramuscular twice weekly, but dosing frequency hasn't been systematically optimized. It's possible that more frequent administration (daily) or less frequent (once weekly) could produce different thymic restoration kinetics. Thymalin's half-life is approximately 6–8 hours, which means plasma levels decline rapidly after injection, but the downstream effects on thymic epithelial FOXN1 expression likely persist for 48–72 hours based on transcription factor regulation timelines. Research protocols examining dose-response relationships should test 5mg daily, 10mg twice weekly, and 20mg once weekly in parallel arms with identical baseline immune markers and measurement timepoints. The twice-weekly protocol emerged from Soviet-era gerontology research and was adopted by 2026 studies for continuity, but it may not be the optimal schedule for maximizing thymic restoration or minimizing injection burden in longer-term studies.

Switch to single-dose protocol immediately: withdraw only the amount needed for one injection, then discard the entire remaining vial. Without benzyl alcohol preservative, each needle puncture introduces contamination risk with zero bacterial growth inhibition, making the solution unsafe for storage beyond 6 hours even under refrigeration. If you've already stored the reconstituted peptide for multiple days, visual clarity is not sufficient to confirm safety. Bacterial counts below the threshold for visible turbidity can still reach levels that trigger inflammatory responses or enzymatic peptide degradation. For compounds like Tesamorelin or CJC-1295 with complex disulfide structures, bacterial protease contamination can fragment the peptide chain without producing visible changes.

Recalculate your cumulative benzyl alcohol exposure. At 0.9% concentration, 5mL of BAC water delivers 45mg of benzyl alcohol, and adult safety thresholds are approximately 30mg/kg/day. For a 70kg subject, that threshold is 2,100mg/day, so 5mL delivers only 2% of the toxic dose. High-volume protocols become problematic only when total daily BAC water volume exceeds 50mL in adult subjects or 10mL in pediatric models. If your protocol requires volumes above those thresholds, reformulate the peptide at higher concentration to reduce diluent volume per dose, or switch to preservative-free SWFI with same-day use requirements.

Discard it. Follistatin-344 degrades rapidly above 8°C. 48 hours at room temperature (20–25°C) denatures approximately 60–70% of the active peptide through thermal unfolding of the protein tertiary structure. Even if refrigerated afterward, the damage is irreversible. Denatured follistatin loses binding affinity for myostatin, making the solution biologically inert. There is no visual indication of degradation. The liquid remains clear. So temperature excursions often go undetected until expected results fail to materialize weeks into a protocol.

Discard it immediately. Cloudiness or visible particulate matter indicates one of three failures: bacterial contamination, peptide aggregation due to temperature excursion, or manufacturing defect. Bacteriostatic water inhibits bacterial growth but does not sterilize already-contaminated solutions—if aseptic technique failed during reconstitution or if the lyophilized powder was compromised before mixing, bacterial proliferation can occur. Aggregation happens when peptides denature and clump together, typically after exposure to temperatures above 25°C or freeze-thaw cycles. Aggregated peptides are biologically inactive and potentially immunogenic. No amount of re-mixing or filtering will restore activity. The financial loss of discarding a vial is negligible compared to the research timeline loss from using degraded material and attributing failed results to the peptide rather than storage failure.

Administer follistatin-344 only when myostatin inhibition serves a defined research goal. Satellite cell activation and hypertrophy require mechanical stimulus to drive meaningful outcomes. Follistatin-344 removes the myostatin brake on muscle protein synthesis, but synthesis itself requires amino acid availability and mTOR activation triggered by resistance training or rehabilitative loading. Studies using follistatin-344 in sedentary models show minimal lean mass changes because the peptide creates permissive conditions for growth without driving growth directly. Myostatin inhibition is necessary but not sufficient for hypertrophy without training stimulus.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors that increase intracellular NAD+ through the salvage pathway, but they are not equivalent to direct NAD+ administration. NMN must be converted to NAD+ via NMNAT enzymes, and NR requires two enzymatic steps (phosphorylation to NMN, then conversion to NAD+). Both precursors elevate NAD+ levels effectively, but peak plasma concentration occurs 2–4 hours post-administration compared to 30–60 minutes for NAD+ itself. If you substitute NMN or NR when you stack with Epithalon, administer the precursor 90–120 minutes before Epithalon to allow time for enzymatic conversion and SIRT1 activation.

Recalculate your injection volume based on current concentration rather than reconstituting a new vial. If you mixed 10mg Tirzepatide with 2mL BAC water (5mg/mL concentration) but now need to increase from 2.5mg to 5mg weekly, simply draw 1mL instead of 0.5mL. The only constraint is injection volume comfort. Doses requiring more than 1.5mL per injection should be split into two injection sites. For dose decreases, the existing concentration works fine; just draw smaller volumes. This flexibility is why calculating concentration before reconstitution matters more than following generic mixing instructions.

No legal pathway exists for personal or recreational use of follistatin-344 in contexts outside IRB-approved research protocols or licensed compounding under a valid prescription for an investigational indication. The follistatin-344 safety profile is insufficient to support unmonitored use. Adverse events that occur outside clinical supervision cannot be systematically captured, reported, or mitigated. Individuals obtaining follistatin-344 from underground labs or non-licensed sources face risks beyond those characterized in clinical trials: product contamination, incorrect dosing, absence of sterility assurance, and lack of medical oversight if adverse events occur. Real Peptides provides research-grade peptides exclusively for approved investigational use and does not support, condone, or supply products for personal administration outside lawful research contexts. Researchers have a duty to educate participants on the distinction between investigational peptides and approved therapeutics, and to explicitly prohibit off-protocol use.

Obtain baseline hormone panels including FSH, LH, estradiol, and progesterone before the first dose, and repeat these measurements at 4-week intervals throughout the study period. Follistatin-344's binding to activin. A key regulator of the menstrual cycle. Creates theoretical risk for ovulatory dysfunction, though no human data exist to quantify this risk. Require participants to use barrier contraception throughout the study and for at least 90 days following the final dose, as the half-life of AAV-delivered follistatin expression extends well beyond the injection date. Monitor for menstrual irregularities, breakthrough bleeding, or amenorrhea, and discontinue the intervention if cycle disruption persists beyond two consecutive cycles. Pregnancy during follistatin-344 exposure should be considered a protocol violation requiring immediate cessation and comprehensive fetal monitoring, as reproductive toxicity studies in humans are non-existent.

This is expected for most peptide classes. Measure the right endpoint at the right time. If you're working with a GLP-1 agonist and tracking body weight or HbA1c, the first week shows appetite modulation—not the downstream metabolic adaptation those hormones trigger. The STEP-1 trial published in the New England Journal of Medicine demonstrated 14.9% mean body weight reduction at 68 weeks on semaglutide, not 68 hours. Early-phase endpoints (satiety, gastric emptying) appear within days; late-phase endpoints (fat oxidation, insulin sensitivity normalization) require 8-12 weeks minimum. If your protocol design expected week-one results for a peptide with a five-day half-life and a mechanism requiring sustained receptor occupancy, the timeline was misaligned from the start.

Use the reconstituted peptide within 24 hours and refrigerate immediately. Sterile water lacks bacteriostatic preservative, meaning bacterial contamination begins within 48 hours of vial puncture even under refrigeration—bacteria enter through the needle puncture site and the stopper's rubber septum. Enzymatic degradation from bacterial peptidases will fragment the peptide sequence into inactive metabolites. If you cannot complete the experimental protocol within 24 hours, discard the solution and reconstitute a fresh vial with proper BAC water. Do not attempt to transfer the peptide to a new vial containing BAC water—contamination has already occurred, and benzyl alcohol cannot reverse enzymatic cleavage.

Mildly elevated VIP (100–150 pg/mL; reference <75 pg/mL) without clinical symptoms warrants investigation before research clearance. VIP levels rise postprandially and with stress, so confirm the elevation with a fasting morning draw. Persistent elevation without secretory diarrhea can indicate subclinical VIPoma, pancreatic neuroendocrine tumor precursors, or VPAC receptor polymorphisms that alter VIP clearance. Obtain chromogranin A, pancreatic protocol CT or MRI, and gastroenterology referral. If imaging is negative and chromogranin A is normal, the subject may have idiopathic hypersecretion. A relative VIP contraindication. Administering exogenous VIP on top of endogenous elevation increases total exposure unpredictably and raises the risk of fluid/electrolyte disturbance even without baseline diarrhea. Consider dose reduction (50% of standard protocol dose) with close monitoring, or exclude the subject entirely if the research timeline doesn't allow extended workup.

Satellite cell activation without subsequent hypertrophy indicates a block at the differentiation or fusion stage. This is rare but documented in models with chronic inflammation, glucocorticoid exposure, or inadequate nutritional support. Satellite cells may proliferate but fail to fuse if the local microenvironment (pH, cytokine profile, extracellular matrix integrity) is hostile. A 2021 paper in Cell Metabolism identified that TNF-alpha (a pro-inflammatory cytokine) directly inhibits myoblast fusion even when satellite cell numbers are elevated. Meaning inflammation can completely decouple activation from hypertrophy. The research implication: follistatin-344 timelines assume a permissive metabolic environment; if inflammation, cortisol, or nutrient deficiency is present, the expected timeline extends or stalls entirely.

Place the vial in the refrigerator and allow passive dissolution over 10–15 minutes. Do not shake, heat, or use a vortex mixer. Forced agitation denatures peptide structure. Some lyophilised peptides, particularly those with high hydrophobic amino acid content like Melanotan 2 or Hexarelin, dissolve more slowly than hydrophilic peptides. If visible powder remains after 30 minutes of refrigerated passive dissolution, the peptide may have been denatured during lyophilisation or shipping. Contact the supplier for replacement.

Verify peptide purity and confirm proper reconstitution protocols immediately. Follistatin-344 is a 344-amino-acid protein prone to aggregation if reconstituted in solutions lacking appropriate buffering agents or stored above 4°C for extended periods. Inconsistent in vitro myostatin binding assays or variable satellite cell proliferation responses almost always trace back to peptide degradation or dimerization. Research teams should request certificates of analysis confirming >98% purity by HPLC, mass spectrometry verification of correct molecular weight, and endotoxin testing below 1 EU/mg. Real Peptides provides batch-specific documentation for every research peptide, including Epithalon Peptide and FOXO4 DRI, ensuring reproducibility across experiments.